



# DIAGNOS

Your Knowledge Partner

**PRESS RELEASE**

OTCQB: DGNOF  
TSXV : ADK  
SOURCE : DIAGNOS Inc.

2018.09.18

## DIAGNOS to Provide Retinal Image Analysis using its AI Technology to 20/20NOW, the Leading Ocular Telehealth Provider in the United States

Brossard, Quebec, Canada – September 18<sup>th</sup>, 2018 - Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today a three-year agreement to provide its CARA (Computer Assisted Retina Analysis) to 20/20NOW. 20/20NOW will use CARA to upload their retinal images and retrieve the results after analysis by our algorithms to detect anomalies caused by diabetic retinopathy in real time. Identifying diabetic retinopathy (“DR”) in its early stages, when it’s most treatable, is critical to prevent blindness and help at lowering health care costs.

“At DIAGNOS, we’re pleased to welcome an innovative company, 20/20NOW, as a new customer and business partner. We also want to extend a warm welcome to their network of more than 60 customers located across the United States. We will exclusively provide rapid and early detection of DR to their customers in the optical space. As 20/20NOW expands their network, we will provide them with fast and reliable detection of DR. As we introduce new healthcare applications, we will work with 20/20NOW to leverage their network and provide early detection of other illnesses to the benefit of their patients.” said Yves-Stephane Couture, Vice-President of Sales at DIAGNOS.

Telehealth industry veteran and 20/20NOW CEO, Chuck Scott, stated “Our mission at 20/20NOW is to expand access to comprehensive eye exams while also improving the standard of care, at a lower cost to our patients. Through the use of cutting-edge AI technology provided by DIAGNOS, our Ocular Telehealth eye exams represent a cost-effective tool to help solve one of the most pressing health care issue in our country today.”

Mr. Scott further stated “The opportunity exists to combine the use of AI and Ocular Telehealth to cost effectively screen and detect other critical health diseases beyond diabetic retinopathy. We believe there will be a vast array of ocular diseases that can be detected through AI and retinal screenings in the future. We look forward to partnering with DIAGNOS to bring these capabilities to market.”

### About 20/20NOW

20/20NOW is the pioneer and innovator of ocular telehealth. Using state-of-the-art technology, proprietary software and patented exam processes, 20/20NOW provides comprehensive eye exams, including eye health screenings, via telehealth. The company’s telehealth model allows eye care professionals and optical retailers to provide their patients with increased access to high quality eye exams at a lower cost.

Additional information is available at [www.for2020now.com](http://www.for2020now.com).



**DIAGNOS**

Your Knowledge Partner

**PRESS RELEASE**

**OTCQB: DGNOF**  
**TSXV: ADK**  
**SOURCE: DIAGNOS Inc.**

About DIAGNOS

DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.

Additional information is available at [www.diagnos.com](http://www.diagnos.com) and [www.sedar.com](http://www.sedar.com)

For further information, please contact:

Mr. André Larente, President  
DIAGNOS Inc.  
Tel: 450-678-8882 ext. 224  
[alarente@diagnos.ca](mailto:alarente@diagnos.ca)

Josh Falle  
Momentum PR  
Tel: 514-416-4656  
[josh@momentumpr.com](mailto:josh@momentumpr.com)

*This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.*

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*